<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577275</url>
  </required_header>
  <id_info>
    <org_study_id>NST-01</org_study_id>
    <nct_id>NCT03577275</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval</brief_title>
  <official_title>A Randomised, Partially Double Blind, Placebo and Positive Controlled, 4 Way Crossover Study to Evaluate the Effect of Icosabutate (NST 4016) on the QT/QTc Interval in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthSea Therapeutics B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthSea Therapeutics B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single centre, randomised, double blind (except for moxifloxacin), placebo
      and positive controlled, 4 way crossover study assessing the ECG effects of therapeutic and
      supratherapeutic doses of icosabutate in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Fridericia's Correction for QT Interval (QTcF)</measure>
    <time_frame>24 hours</time_frame>
    <description>Electrocardiogram measurement of the maximum absolute change from baseline in Fridericia's correction for QT interval (QTcF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate (HR)</measure>
    <time_frame>24 hours</time_frame>
    <description>Electrocardiogram measurement of change from baseline in heart rate (HR) maximum values presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fridericia's Correction for QT Interval (QTcF)</measure>
    <time_frame>24 hours</time_frame>
    <description>Electrocardiogram measurement of change from baseline in Fridericia's correction for QT interval (QTcF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR Interval (PR)</measure>
    <time_frame>24 hours</time_frame>
    <description>Electrocardiogram measurement of change from baseline in PR interval (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QRS Interval (QRS)</measure>
    <time_frame>2 hours</time_frame>
    <description>Electrocardiogram measurement of change from baseline in QRS interval (QRS)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo to match NST-4016</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 400mg dose of active comparator moxifloxacin (open label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NST-4016 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Likely therapeutic dose of NST-4016</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NST-4016 2000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supratherapeutic dose of NST-4016</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NST-4016 600mg</intervention_name>
    <description>Likely maximum therapeutic dose of NST-4016</description>
    <arm_group_label>NST-4016 600mg</arm_group_label>
    <other_name>Icosabutate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400mg</intervention_name>
    <description>Active comparator with known effect on QT interval</description>
    <arm_group_label>Moxifloxacin 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NST-4016 2000mg</intervention_name>
    <description>Supratherapeutic dose of NST-4016</description>
    <arm_group_label>NST-4016 2000mg</arm_group_label>
    <other_name>Icosabutate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Males or females, of any race, between 18 and 55 years of age, inclusive, at
             Screening.

          -  2. Body mass index (BMI) between 18.0 and 33.0 kg/m2, inclusive, at Screening

          -  3. In good health

        Exclusion Criteria:

          -  1. An uninterpretable or abnormal ECG at Screening and/or Check in

          -  2. History of risk factors for Torsades de Pointes

          -  3. sustained supine systolic blood pressure &gt;140 mmHg or &lt;90 mmHg

          -  4. Unstable cardiovascular disease, including recent myocardial infarction or cardiac
             arrhythmia.

          -  5. Female subjects who are pregnant (or planning to become pregnant within 90 days
             after the final dose administration) or are currently lactating

          -  6. Subjects who, in the opinion of the Investigator (or designee), should not
             participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Ltd</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <results_first_submitted>July 31, 2019</results_first_submitted>
  <results_first_submitted_qc>November 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03577275/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03577275/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a cross over study so 32 subjects each completed 4 treatment arms</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>This was a 4 way crossover study in which all study participants received the following treatments in random order; NST-4016 2000mg: Supratherapeutic dose of NST-4016, NST-4016 600mg: Likely maximum therapeutic dose of NST-4016, Moxifloxacin 400mg: Active comparator with known effect on QT interval, Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects. There were 12 possible treatment sequences</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">All participants received all of the 4 interventions</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Moxifloxacin 400mg</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NST-4016 600mg</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NST-4016 2000mg</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants were randomized to receive all 4 interventions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fridericia's Correction for QT Interval (QTcF)</title>
        <description>Electrocardiogram measurement of the maximum absolute change from baseline in Fridericia's correction for QT interval (QTcF)</description>
        <time_frame>24 hours</time_frame>
        <population>The primary endpoint for this trial was the placebo corrected change from baseline in QTcF. The data presented here are the maximum absolute change from baseline for placebo, moxifloxacin 400mg, NST-4016 600mg and NST-4016 2000mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Capsule</title>
            <description>Single dose of placebo to match NST-4016
Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin 400mg</title>
            <description>Single 400mg dose of active comparator moxifloxacin (open label)
Moxifloxacin 400mg: Active comparator with known effect on QT interval</description>
          </group>
          <group group_id="O3">
            <title>NST-4016 600mg</title>
            <description>Likely therapeutic dose of NST-4016
NST-4016 600mg: Likely maximum therapeutic dose of NST-4016</description>
          </group>
          <group group_id="O4">
            <title>NST-4016 2000mg</title>
            <description>Supratherapeutic dose of NST-4016
NST-4016 2000mg: Supratherapeutic dose of NST-4016</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fridericia's Correction for QT Interval (QTcF)</title>
          <description>Electrocardiogram measurement of the maximum absolute change from baseline in Fridericia's correction for QT interval (QTcF)</description>
          <population>The primary endpoint for this trial was the placebo corrected change from baseline in QTcF. The data presented here are the maximum absolute change from baseline for placebo, moxifloxacin 400mg, NST-4016 600mg and NST-4016 2000mg.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="1.52"/>
                    <measurement group_id="O2" value="11.5" spread="0.88"/>
                    <measurement group_id="O3" value="-6.0" spread="1.39"/>
                    <measurement group_id="O4" value="-6.1" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was based on concentration-QTc modeling of the relationship between icosabutate and delta delta QTcF, with the intent to exclude an effect &gt; 10 msec at clinically relevant icosabutate plasma concentrations.
Assay sensitivity was evaluated by concentration-QTc analysis of the effect on delta delta QTcF of moxifloxacin using a similar model as for the primary analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>The primary analysis was based on concentration-QTc modeling of the relationship between icosabutate and delta delta QTcF, with the intent to exclude an effect &gt; 10 msec at clinically relevant icosabutate plasma concentrations.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate (HR)</title>
        <description>Electrocardiogram measurement of change from baseline in heart rate (HR) maximum values presented</description>
        <time_frame>24 hours</time_frame>
        <population>maximum values of change in heart rate from baseline over the 24 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo to match NST-4016 Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin 400mg</title>
            <description>Single 400mg dose of active comparator moxifloxacin (open label) Moxifloxacin 400mg: Active comparator with known effect on QT interval</description>
          </group>
          <group group_id="O3">
            <title>NST-4016 600mg</title>
            <description>Likely therapeutic dose of NST-4016 NST-4016 600mg: Likely maximum therapeutic dose of NST-4016</description>
          </group>
          <group group_id="O4">
            <title>NST-4016 2000mg</title>
            <description>Supratherapeutic dose of NST-4016 NST-4016 2000mg: Supratherapeutic dose of NST-4016</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate (HR)</title>
          <description>Electrocardiogram measurement of change from baseline in heart rate (HR) maximum values presented</description>
          <population>maximum values of change in heart rate from baseline over the 24 hours post dose</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="0.86"/>
                    <measurement group_id="O2" value="12.2" spread="0.85"/>
                    <measurement group_id="O3" value="12.6" spread="0.88"/>
                    <measurement group_id="O4" value="15.6" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fridericia's Correction for QT Interval (QTcF)</title>
        <description>Electrocardiogram measurement of change from baseline in Fridericia's correction for QT interval (QTcF)</description>
        <time_frame>24 hours</time_frame>
        <population>The largest change in QTcF for each arm during the study is presented below</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo to match NST-4016 Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin 400mg</title>
            <description>Single 400mg dose of active comparator moxifloxacin (open label) Moxifloxacin 400mg: Active comparator with known effect on QT interval</description>
          </group>
          <group group_id="O3">
            <title>NST-4016 600mg</title>
            <description>Likely therapeutic dose of NST-4016 NST-4016 600mg: Likely maximum therapeutic dose of NST-4016</description>
          </group>
          <group group_id="O4">
            <title>NST-4016 2000mg</title>
            <description>Supratherapeutic dose of NST-4016 NST-4016 2000mg: Supratherapeutic dose of NST-4016</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fridericia's Correction for QT Interval (QTcF)</title>
          <description>Electrocardiogram measurement of change from baseline in Fridericia's correction for QT interval (QTcF)</description>
          <population>The largest change in QTcF for each arm during the study is presented below</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="1.52"/>
                    <measurement group_id="O2" value="11.5" spread="0.88"/>
                    <measurement group_id="O3" value="-6.0" spread="1.39"/>
                    <measurement group_id="O4" value="-5.7" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR Interval (PR)</title>
        <description>Electrocardiogram measurement of change from baseline in PR interval (PR)</description>
        <time_frame>24 hours</time_frame>
        <population>maximum change from baseline during the study period is reported</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo to match NST-4016 Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin 400mg</title>
            <description>Single 400mg dose of active comparator moxifloxacin (open label) Moxifloxacin 400mg: Active comparator with known effect on QT interval</description>
          </group>
          <group group_id="O3">
            <title>NST-4016 600mg</title>
            <description>Likely therapeutic dose of NST-4016 NST-4016 600mg: Likely maximum therapeutic dose of NST-4016</description>
          </group>
          <group group_id="O4">
            <title>NST-4016 2000mg</title>
            <description>Supratherapeutic dose of NST-4016 NST-4016 2000mg: Supratherapeutic dose of NST-4016</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR Interval (PR)</title>
          <description>Electrocardiogram measurement of change from baseline in PR interval (PR)</description>
          <population>maximum change from baseline during the study period is reported</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="1.32"/>
                    <measurement group_id="O2" value="-11.9" spread="1.30"/>
                    <measurement group_id="O3" value="-11.4" spread="1.36"/>
                    <measurement group_id="O4" value="-12.4" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QRS Interval (QRS)</title>
        <description>Electrocardiogram measurement of change from baseline in QRS interval (QRS)</description>
        <time_frame>2 hours</time_frame>
        <population>The data presented is from the 2 hour time point corresponding to T max</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo to match NST-4016 Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin 400mg</title>
            <description>Single 400mg dose of active comparator moxifloxacin (open label) Moxifloxacin 400mg: Active comparator with known effect on QT interval</description>
          </group>
          <group group_id="O3">
            <title>NST-4016 600mg</title>
            <description>Likely therapeutic dose of NST-4016 NST-4016 600mg: Likely maximum therapeutic dose of NST-4016</description>
          </group>
          <group group_id="O4">
            <title>NST-4016 2000mg</title>
            <description>Supratherapeutic dose of NST-4016 NST-4016 2000mg: Supratherapeutic dose of NST-4016</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QRS Interval (QRS)</title>
          <description>Electrocardiogram measurement of change from baseline in QRS interval (QRS)</description>
          <population>The data presented is from the 2 hour time point corresponding to T max</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.17"/>
                    <measurement group_id="O2" value="-0.1" spread="0.16"/>
                    <measurement group_id="O3" value="-0.2" spread="0.17"/>
                    <measurement group_id="O4" value="0.2" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3.5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Oral Capsule</title>
          <description>Single dose of placebo to match NST-4016
Placebo oral capsule: Placebo for comparison with moxifloxacin and potential NST-4016 effects</description>
        </group>
        <group group_id="E2">
          <title>Moxifloxacin 400mg</title>
          <description>Single 400mg dose of active comparator moxifloxacin (open label)
Moxifloxacin 400mg: Active comparator with known effect on QT interval</description>
        </group>
        <group group_id="E3">
          <title>NST-4016 600mg</title>
          <description>Likely therapeutic dose of NST-4016
NST-4016 600mg: Likely maximum therapeutic dose of NST-4016</description>
        </group>
        <group group_id="E4">
          <title>NST-4016 2000mg</title>
          <description>Supratherapeutic dose of NST-4016
NST-4016 2000mg: Supratherapeutic dose of NST-4016</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>One subject (female) experienced an SAE of cerebrovascular accident that began &lt;17 days post the last dose of the study drug (600 mg icosabutate in Dosing Period 4). The Investigator considered the event to be severe and related to the study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disturbance</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Patrick Round</name_or_title>
      <organization>NorthSea Therapeutics BV</organization>
      <phone>+44(0)7979502770</phone>
      <email>patrick.round@northseatherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

